Phio Pharmaceuticals Announces Positive Safety Monitoring Committee (SMC) Recommendation to Continue to Third Dose Cohort in its Clinical Study of PH-762
Portfolio Pulse from
Phio Pharmaceuticals Corp. announced that the Safety Monitoring Committee has recommended continuing to the third dose cohort in its clinical study of PH-762, following a positive safety profile in the second cohort. This development is part of a Phase 1b trial evaluating PH-762 for various cancer treatments.
December 19, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Phio Pharmaceuticals received a positive recommendation from the Safety Monitoring Committee to proceed to the third dose cohort in its PH-762 clinical trial, indicating a strong safety profile.
The positive recommendation from the Safety Monitoring Committee to escalate to the next dose cohort in the PH-762 trial suggests that the drug is demonstrating a favorable safety profile. This is a significant milestone in clinical trials, often leading to increased investor confidence and potential stock price appreciation.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100